PRAECIS PHARMACEUTICALS INCORPORATED Provides Update on Plenaxis ...
WALTHAM, Mass. -- PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ: PRCS), today provided an update on the Company's commercialization of Plenaxis(R) (abarelix for injectable suspension) in the United States. The Company stated that Plenaxis(R) is an important therapy for patients in the indicated population who have limited or no other treatment options available and reported that physician feedback reaffirms that Plenaxis(R) achieves its intended therapeutic goal of providing these patients with a non-surgical option for managing the symptoms of their advanced prostate cancer.